There is an increase in diagnosing and treating patients already carrying active implanted medical devices and brain computer interfaces. No neuro- modulation system available in the market is currently ‘MRI’ safe. The Denecor project will demonstrate coexistency between nano- electronics based diagnosis and therapy systems, thus enabling market acceptance of electromagnetic therapy by removing the main roadblock of incompatibility between the neuromodulation therapy (DBS & TMS) and the neurological diagnostic systems (EEG, MRI & US) inducing a higher preference rate among clinicians.
The clinical partners are fully integrated in the consortium to contribute to the requirements and help develop clinical procedures for adopting and assuring market acceptance of the project innovations. Denecor will accelerate European business, since the consortium will deliver a set of coexistent devices for simultaneous neuro therapy and imaging.
The DeNeCoR project started at June 1, 2013 and finished on November 30, 2016. Excellent results have been achieved. First products already have been announced to the market, others will follow soon or are furhter elaborated in successor projects.